Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 3/20 | 0.33 |
| ▸ | MMP9 | P14780 | 3/20 | 0.33 |
| ▸ | MMP1 | P03956 | 2/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3552692 | 1.00 | SLC2A1 (0.40) | SLC2A1PTGS2PSDMMP2MMP9 | |
| SCHEMBL3561371 | 0.92 | SLC2A1 (0.46) | SLC2A1PTGS2PSDMMP2MMP9 | |
| SCHEMBL3561374 | 0.92 | SLC2A1 (0.46) | SLC2A1PTGS2PSDMMP2MMP9 | |
| SCHEMBL3560081 | 0.88 | SLC2A1 (0.42) | SLC2A1PTGS2PSDKIF11NPBWR1 | |
| SCHEMBL3560079 | 0.88 | SLC2A1 (0.42) | SLC2A1PTGS2PSDKIF11NPBWR1 | |
| SCHEMBL3559270 | 0.87 | SLC2A1 (0.43) | SLC2A1PTGS2PSDMMP2MMP9 | |
| SCHEMBL4472453 | 0.83 | SLC2A1 (0.58) | SLC2A1PTGS2PSDMMP2MMP9 | |
| SCHEMBL13439206 | 0.80 | MLYCD (0.40) | SLC2A1 | |
| SCHEMBL14065684 | 0.80 | SLC2A1 (0.36) | SLC2A1 | |
| SCHEMBL3561397 | 0.80 | SLC2A1 (0.49) | SLC2A1PTGS2PSDMMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674808-B2 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2010-03-09 | — | — | US | claimed |
| EP-2024332-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-02-18 | — | — | EP | claimed |
| EP-1967515-A1 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2008-09-10 | — | — | EP | claimed |
| US-20080021073-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | US | claimed |
| WO-2007138048-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | WO | claimed |
| EP-1862459-A1 | Novel heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2007-12-05 | — | — | EP | claimed |
| US-7674808-B2 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-7674808-B2 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-7674808-B2 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-7629365-B2 | antimalarial agent; 3-chloro-6-(hydroxymethyl)-2-methyl-5-[4-({4-[(trifluoromethyl)oxy]phenyl}oxy)phenyl]-4(1H )-pyridinone | GLAXO GROUP LIMITED (GB) | 2009-12-08 | — | — | US | disclosed |
| US-7629365-B2 | antimalarial agent; 3-chloro-6-(hydroxymethyl)-2-methyl-5-[4-({4-[(trifluoromethyl)oxy]phenyl}oxy)phenyl]-4(1H )-pyridinone | GLAXO GROUP LIMITED (GB) | 2009-12-08 | — | — | US | disclosed |
| US-7629365-B2 | antimalarial agent; 3-chloro-6-(hydroxymethyl)-2-methyl-5-[4-({4-[(trifluoromethyl)oxy]phenyl}oxy)phenyl]-4(1H )-pyridinone | GLAXO GROUP LIMITED (GB) | 2009-12-08 | — | — | US | disclosed |
| EP-1967515-A1 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2008-09-10 | — | — | EP | disclosed |
| US-20080021073-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | US | disclosed |
| US-20080021073-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | US | disclosed |
| WO-2007138048-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | WO | disclosed |
| US-20070281977-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| US-20070281977-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| US-20070281977-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| EP-1862459-A1 | Novel heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2007-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021073-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CYP4B1, CYP3A4, G6PD | SLC2A1 4190/4885PTGS2 1454/4885PSD 4195/4885 |
| US-20070281977-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CYP4B1, CYP2C19, CYP3A4 | SLC2A1 4383/4885PTGS2 1115/4885PSD 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.